Sector News

Ipsen signs option to buy UCL spin-out Canbex

February 24, 2015
Life sciences
France’s Ipsen has bought an option to acquire the UK’s Canbex Therapeutics, which is working on a treatment for spasticity in people with multiple sclerosis.
Canbex is a spin-off of University College London that raised £2.3 million in 2013 from MS Ventures (the corporate venture arm of Merck KGaA), the Wellcome Trust and UCL Business. The therapy in question, called VSN16R, which has been shown in preclinical and Phase I studies to have the potential to provide substantially better patient care than existing systemic anti-spastic treatments, Ipsen says.
Ipsen has paid 6 million euros for the option to acquire Canbex at completion of a Phase IIa study. The latter’s present shareholders will be eligible to receive up to an additional 90 million euros, comprising an acquisition payment, plus royalties on VSN16R.
Ipsen chief executive Marc de Garidel said Canbex’ lead compound “has demonstrated excellent safety, efficacy and tolerability to date and fits well within our neurology franchise”. He added that “it could be a valuable companion product” to his company’s wrinkles and cervical dystonia treatment Dysport (abobotulinumtoxin A) in the treatment of spasticity.
By Kevin Grogan
Source: Pharma Times

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]